<DOC>
	<DOCNO>NCT01687595</DOCNO>
	<brief_summary>The purpose study evaluate effect HerpV vaccine recur episode genital herpes evaluate viral shedding , treatment .</brief_summary>
	<brief_title>Biological Efficacy Study HerpV Vaccine With QS-21 Treat Subjects With Recurrent Genital Herpes</brief_title>
	<detailed_description>This study evaluate biological effectiveness safety HerpV vaccine combination adjuvant QS-21 . The Safety tolerability HerpV plus QS-21 also evaluate collect number severity adverse event throughout study . Biological effectiveness evaluate compare viral shed rate treatment period compare baseline period study . Subjects undergo baseline/ screen period . This 45 day period subject collect swab genital area day . . In case recurrence , subject require collect two swabs day . If subject collect least 80 % swab sample meet eligibility criterion may enroll study . Subjects meet inclusion exclusion criterion enrol randomized Study Period 1 ( treatment period ) . In order assure trial enrolls good representation woman men , prespecified cap woman set 50 ( approximately 67 % total enrolled population . ) Study Period 1 consists three treatment 45 day swab period last treatment . The subject collect swab genital region day 45 day . Subjects successfully complete Study Period 1 proceed Study Period 2 . They receive booster injection study drug placebo accord orginal randomization assignment . The subject enter 45 day swab period , collect swabs genital area day 45 day . To evaluate immunologic response subject require blood drawn various time point study . Subjects require suspend suppressive antiviral therapy duration study ( week 48 ) . For one week 45 day swab period subject also require suspend episodic antiviral therapy .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Herpes Genitalis</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>Seropositive HSV2 Clinically active genital herpes define history 19 episode per year least one year prior screen one year prior begin suppressive therapy . Willing either use effective method contraception abstain sexual intercourse throughout 48 week study period . If female childbearing potential , negative serum pregnancy test . Agree receive investigational drug enrol study . The criterion must meet subject allow enter 45 day swab period screen study . Completion great equal 80 % ( 36 day ) 45 day consecutive daily genital swab . Severe active infection , compromise cardiopulmonary function , serious medical illness , opinion Principal Investigator , would prevent study completion . A history HSV infection eye ( herpes simplex interstitial keratitis uveitis ) , herpesassociated erythema multiforme . A history immune suppression autoimmune disorder . Continued use suppressive antiviral therapy HSV2 ; one week washout antiviral therapy ( suppressive episodic ) require prior initiate swabbing period . Concomitant use systemic corticosteroid immunesuppressive medication . The use nasal steroid acceptable . HIV positive . Presence active Hepatitis B C infection . Known hypersensitivity allergy acyclovir valacyclovir . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>herpes simplex virus type 2 ,</keyword>
	<keyword>genital herpes</keyword>
</DOC>